HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.

AbstractOBJECTIVES:
Vestibular schwannomas are the hallmark of neurofibromatosis type two. They are difficult to treat, due to their bilateral presentation and the quest for hearing preservation. Our report describes a new treatment approach in this clinical scenario.
CASE REPORT:
We report two cases which confirm that bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, causes regression of vestibular schwannomas in patients with a previous history of gamma knife radiosurgery or failed treatment with another form of vascular endothelial growth factor targeted therapy.
CONCLUSION:
In 2009, Plotkin et al. reported the volumetric response of vestibular schwannomas to bevacizumab treatment, both in untreated patients and in patients previously treated with erlotinib, an epidermal growth factor receptor inhibitor. The presented cases support the use of bevacizumab to treat vestibular schwannomas. Given the extremely slow growth of these tumours, we note the rapidity of volume reduction following bevacizumab therapy.
AuthorsG K Eminowicz, R Raman, J Conibear, P N Plowman
JournalThe Journal of laryngology and otology (J Laryngol Otol) Vol. 126 Issue 1 Pg. 79-82 (Jan 2012) ISSN: 1748-5460 [Electronic] England
PMID22004800 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Contrast Media
  • Vascular Endothelial Growth Factors
  • Bevacizumab
  • Gadolinium
Topics
  • Adult
  • Angiogenesis Inhibitors (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal, Humanized (administration & dosage, therapeutic use)
  • Bevacizumab
  • Contrast Media
  • Female
  • Gadolinium
  • Hearing Loss, Unilateral (etiology, prevention & control)
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Neurofibromatosis 2 (complications, drug therapy, radiotherapy, surgery)
  • Neuroma, Acoustic (drug therapy, etiology, radiotherapy, surgery)
  • Radiosurgery (instrumentation)
  • Remission Induction (methods)
  • Treatment Outcome
  • Vascular Endothelial Growth Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: